Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.

[1]  Bramahn . Singh,et al.  Controlling Cardiac Arrhythmias by Lengthening Repolarization: Rationale from Experimental Findings and Clinical Considerations a , 1992, Annals of the New York Academy of Sciences.

[2]  Bramahn . Singh,et al.  Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction. , 1990, The American journal of cardiology.

[3]  D. Berry,et al.  A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. , 1990, American heart journal.

[4]  S Nattel,et al.  Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. , 1990, Circulation.

[5]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[6]  R. Kehoe,et al.  Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. , 1990, The American journal of cardiology.

[7]  J. Anderson.  Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs. , 1990, The American journal of cardiology.

[8]  B. Singh,et al.  Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents. , 1990, American Journal of Cardiology.

[9]  P. Deedwania.  Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes. , 1990, The American journal of cardiology.

[10]  B. Singh,et al.  Expanding clinical role of unique class III antiarrhythmic effects of sotalol. , 1990, The American journal of cardiology.

[11]  R. Lux,et al.  Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. , 1989, Circulation.

[12]  J. Kupersmith,et al.  Dextrorotatory isomer of sotalol: electrophysiologic effects and interaction with verapamil. , 1988, American heart journal.

[13]  K. Nademanee,et al.  Sotalol: a beta blocker with unique antiarrhythmic properties. , 1987, American heart journal.

[14]  T. Campbell.  Cellular electrophysiological effects of d‐and dl‐sotalol in guinea‐pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity , 1987, British journal of pharmacology.

[15]  J. Goy,et al.  Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. , 1986, The American journal of cardiology.

[16]  A. Camm,et al.  Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. , 1986, The American journal of cardiology.

[17]  M. Lakhal,et al.  Protection against ventricular and atrial fibrillation by sotalol. , 1986, Cardiovascular research.

[18]  G. D. Johnston,et al.  A comparison of the cardiovascular effects of (+)-sotalol and (+/-)-sotalol following intravenous administration in normal volunteers. , 1985, British journal of clinical pharmacology.

[19]  K. Nademanee,et al.  Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. , 1985, Circulation.

[20]  M. Shimotori,et al.  Comparative study of five beta-adrenoceptor blocking agents on sinoatrial conduction time in isolated blood-perfused canine atria. , 1985, Archives internationales de pharmacodynamie et de therapie.

[21]  J. Valty,et al.  [Electrophysiological effects of intravenous sotalol. Relation with plasma levels]. , 1985, Archives des maladies du coeur et des vaisseaux.

[22]  E. Carmeliet.  Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[23]  K. Nademanee,et al.  Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. , 1985, American heart journal.

[24]  B. Lucchesi,et al.  Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. , 1984, Journal of cardiovascular pharmacology.

[25]  S. Kimura,et al.  Effects of nipradilol (K-351) on the electrophysiological properties of canine cardiac tissues: comparison with propranolol and sotalol. , 1984, European journal of pharmacology.

[26]  B. Lucchesi,et al.  Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol. , 1984, The Journal of pharmacology and experimental therapeutics.

[27]  D. Sheridan,et al.  Effects of sotalol on arrhythmias and electrophysiology during myocardial ischaemia and reperfusion. , 1984, Cardiovascular research.

[28]  P. Touboul,et al.  Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. , 1984, American heart journal.

[29]  J. Brachmann,et al.  Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. , 1984, The American journal of cardiology.

[30]  J. Brachmann,et al.  Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. , 1984, Circulation.

[31]  J. Brachmann,et al.  Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. , 1983, Circulation.

[32]  Bramahn . Singh,et al.  Amiodarone: historical development and pharmacologic profile. , 1983, American heart journal.

[33]  R. Marshall,et al.  Effects of antiarrhythmic drugs on ventricular fibrillation thresholds of normal and ischaemic myocardium in the anaesthetized rat , 1983, British journal of pharmacology.

[34]  M. Lewis,et al.  Inotropic beta-blocking potency (pA2) and partial agonist activity of propranolol, practolol, sotalol and acebutolol. , 1982, European journal of pharmacology.

[35]  D. Harrison,et al.  Prolongation of the human cardiac monophasic action potential by sotalol. , 1982, The American journal of cardiology.

[36]  A. Camm,et al.  Electrophysiological effects of sotalol--just another beta blocker? , 1982, British heart journal.

[37]  S. Olsson,et al.  Sotalol-induced delayed ventricular repolarization in man. , 1980, European heart journal.

[38]  L. Horowitz,et al.  Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmia. , 1980, Progress in cardiovascular diseases.

[39]  A. Camm,et al.  The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride , 1979, Clinical cardiology.

[40]  S. Epstein,et al.  Comparison of relative inotropic and chronotropic effects of propranolol, practolol, and sotalol. , 1973, Chest.

[41]  E. Braunwald,et al.  Comparative effects of sotalol and propranolol on myocardial contractility. , 1973, Archives internationales de pharmacodynamie et de therapie.

[42]  W. Parmley,et al.  Comparative effects of sotalol and propranolol on contractility of papillary muscles and adenyl cyclase activity of myocardial extracts of cat. , 1972, The Journal of clinical pharmacology and new drugs.

[43]  A. Barrett,et al.  Comparative chronotropic activity of β‐adrenoceptive antagonists , 1970 .

[44]  B. Singh,et al.  The effect of amiodarone, a new anti‐anginal drug, on cardiac muscle , 1970, British journal of pharmacology.

[45]  B. Singh,et al.  A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 , 1970, British journal of pharmacology.

[46]  J. Bigger,et al.  Electrophysiological and Beta‐Receptor Blocking Effects of MJ 1999 on Dog and Rabbit Cardiac Tissue , 1970, Circulation research.

[47]  N. Svedmyr,et al.  A comparative study of some cardiovascular effects of sotalol (MJ 1999) and propranolol. , 1969, Life sciences.

[48]  P. Somani,et al.  Antiarrhythmic activity of the dextro- and levorotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide (MJ 1999). , 1968, Journal of Pharmacology and Experimental Therapeutics.

[49]  C. Olson,et al.  Temporal Relation Between Long-Lasting Aftercontractions and Action Potentials in Cat Papillary Muscles , 1968, Science.

[50]  J. R. Schmid,et al.  A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol. , 1967, The Journal of pharmacology and experimental therapeutics.

[51]  J. R. Blinks.  EVALUATION OF THE CARDIAC EFFECTS OF SEVERAL BETA ADRENERGIC BLOCKING AGENTS , 1967, Annals of the New York Academy of Sciences.

[52]  P. M. Lish,et al.  Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. , 1965, The Journal of pharmacology and experimental therapeutics.

[53]  J. Cummings,et al.  Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.

[54]  A. Jervell,et al.  Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death , 1957 .

[55]  S. Yabek,et al.  Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. , 1986, Journal of the American College of Cardiology.

[56]  S. Cobbe,et al.  Effects of elevated extracellular potassium concentrations on the class III antiarrhythmic action of sotalol. , 1985, Cardiovascular research.

[57]  B. Lucchesi,et al.  Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog. , 1984, Pharmacology.